Johnson & Johnson to acquire Abiomed for $380/share plus CVR; enterprise value ~$16.6B

JOHNSON & JOHNSON

Upfront cash $380/share + CVR up to $35/share; total implied value ~$415/share.
Enterprise value ~$16.6B including cash acquired; deal expected to close by mid-2023.
CVR milestones: net sales >$3.7B; FDA approval for Impella in STEMI; Class I guidelines.
Transaction broadens JNJ MedTech cardiovascular portfolio; accretive to adjusted EPS in 2024.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.99

JOHNSON & JOHNSON entered into Agreement and Plan of Merger with ABIOMED, Inc. valued at Johnson & Johnson to acquire all outstanding shares of ABIOMED for $380.00 per share in cash plus on (effective 2022-10-31).

Action: entry
Agreement: merger
Counterparty: ABIOMED, Inc.
Value: Johnson & Johnson to acquire all outstanding shares of ABIOMED for $380.00 per share in cash plus on
Effective: 2022-10-31

Exact text from the filing

Item 1.01 Entry into a Material Definitive Agreement Agreement and Plan of Merger On October 31, 2022, Johnson & Johnson, a New Jersey corporation (“ Johnson & Johnson ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Athos Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Johnson & Johnson (“ Merger Sub ”), and ABIOMED, Inc., a Delaware corporation (“ ABIOMED ”).

View on SEC.gov

Browse all material agreements →

JOHNSON & JOHNSON filing history →

Source: SEC EDGAR

accession 0001193125-22-274491

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.